Table 3.
Cox multivariate analysis evaluating high risk classification by American Joint Committee on Cancer (AJCC) stage (stage IIB and above) along with gene expression profile class
| HR | 95% CI | P‐value | ||
|---|---|---|---|---|
| RFS | ≥AJCC stage IIB | 2.9 | 0.2‐0.6 | .0003 |
| GEP Class 2 | 2.8 | 1.5‐5.1 | .0009 | |
| DMFS | ≥ AJCC stage IIB | 2.4 | 0.2‐0.8 | .006 |
| GEP Class 2 | 2.8 | 1.5‐5.4 | .002 | |
| OS | ≥ AJCC stage IIB | 2.8 | 0.2‐0.7 | .005 |
| GEP Class 2 | 4.1 | 1.9‐9.1 | .0004 | |
| MSS | ≥ AJCC stage IIB | 2.3 | 0.2‐1.1 | .1 |
| GEP Class 2 | 6.8 | 1.8‐25.4 | .005 |
Abbreviations: DMFS, distant metastasis‐free survival; GEP, gene expression profile; MSS, melanoma‐specific survival; OS, overall survival; RFS, recurrence‐free survival.